Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine
- PMID: 20375242
- PMCID: PMC2884420
- DOI: 10.1128/CVI.00027-10
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine
Abstract
Invasive disease caused by meningococcal capsular groups A, C, W-135, and Y is now preventable by means of glycoconjugate vaccines that target their respective polysaccharide capsules. The capsule of group B meningococci (MenB) is poorly immunogenic and may induce autoimmunity. Vaccines based on the major immunodominant surface porin, PorA, are effective against clonal epidemics but, thus far, have a limited scope of coverage against the wider MenB population at large. In an alternative approach, the first-generation, investigational, recombinant MenB (rMenB) plus outer membrane vesicle (OMV) (rMenB-OMV) vaccine contains a number of relatively conserved surface proteins, fHBP, NHBA (previously GNA2132), and NadA, alongside PorA P1.4-containing OMVs from the New Zealand MeNZB vaccine. MenB currently accounts for approximately 90% of cases of meningococcal disease in England and Wales. To assess potential rMenB-OMV vaccine coverage of pathogenic MenB isolates within this region, all English and Welsh MenB case isolates from January 2008 (n = 87) were genetically characterized with respect to fHBP, NHBA, NadA, and PorA. Alleles for fHbp, nhba, and porA were identified in all of the isolates, of which 22% were also found to harbor nadA alleles. On the basis of genotypic data and predicted immunological cross-reactivity, the potential level of rMenB-OMV vaccine coverage in England and Wales ranges from 66% to 100%.
Figures






Similar articles
-
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales.J Clin Microbiol. 2009 Nov;47(11):3577-85. doi: 10.1128/JCM.00936-09. Epub 2009 Sep 16. J Clin Microbiol. 2009. PMID: 19759227 Free PMC article.
-
Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014.Hum Vaccin Immunother. 2024 Dec 31;20(1):2378537. doi: 10.1080/21645515.2024.2378537. Epub 2024 Jul 22. Hum Vaccin Immunother. 2024. PMID: 39037011 Free PMC article.
-
Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.mBio. 2019 Sep 10;10(5):e01668-19. doi: 10.1128/mBio.01668-19. mBio. 2019. PMID: 31506309 Free PMC article.
-
Meningococcal serogroup B vaccines: Estimating breadth of coverage.Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Hum Vaccin Immunother. 2017. PMID: 27960595 Free PMC article. Review.
-
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.Vaccine. 2012 May 30;30 Suppl 2(0 2):B87-97. doi: 10.1016/j.vaccine.2012.01.033. Vaccine. 2012. PMID: 22607904 Free PMC article. Review.
Cited by
-
Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil.PLoS One. 2012;7(3):e33016. doi: 10.1371/journal.pone.0033016. Epub 2012 Mar 14. PLoS One. 2012. PMID: 22431994 Free PMC article.
-
Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.Hum Vaccin Immunother. 2013 Nov;9(11):2296-303. doi: 10.4161/hv.25800. Epub 2013 Jul 23. Hum Vaccin Immunother. 2013. PMID: 23880917 Free PMC article.
-
Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.Clin Vaccine Immunol. 2013 Sep;20(9):1360-9. doi: 10.1128/CVI.00090-13. Epub 2013 Jun 26. Clin Vaccine Immunol. 2013. PMID: 23803905 Free PMC article.
-
Diversity of meningococci associated with invasive meningococcal disease in the Republic of Ireland over a 19 year period, 1996-2015.PLoS One. 2020 Feb 13;15(2):e0228629. doi: 10.1371/journal.pone.0228629. eCollection 2020. PLoS One. 2020. PMID: 32053601 Free PMC article.
-
Enhancing Meningococcal Genomic Surveillance in the Meningitis Belt Using High-Resolution Culture-Free Whole-Genome Sequencing.J Infect Dis. 2022 Sep 4;226(4):729-737. doi: 10.1093/infdis/jiac104. J Infect Dis. 2022. PMID: 35325163 Free PMC article.
References
-
- Bambini, S., A. Muzzi, P. Olcen, R. Rappuoli, M. Pizza, and M. Comanducci. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803. - PubMed
-
- Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Froholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096. - PubMed
-
- Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, and J. Mays. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outermembrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13:821-829. - PubMed
-
- Campbell, H., R. Borrow, D. Salisbury, and E. Miller. 2009. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl. 2):B20-B29. - PubMed
-
- Comanducci, M., S. Bambini, B. Brunelli, J. Adu-Bobie, B. Aricò, B. Capecchi, M. M. Giuliani, V. Masignani, L. Santini, S. Savino, D. M. Granoff, D. A. Caugant, M. Pizza, R. Rappuoli, and M. Mora. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454. - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
- GDB/FJ619644
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical